Abstract |
Treatment of relapsed/refractory T cell neoplasms represents an unmet medical need. We recorded, retrospectively, data on 20 consecutive adult patients with T cell neoplasms (8 T cell lymphoma not otherwise specified (T-NOS), 4 angioimmunoblastic (AILT), 3 prolymphocytic leukemia (T-PLL), 3 advance-stage mycosis fungoides (MF) or Sézary syndrome (SS), and 2 T cell large granular lymphocytic leukemia (T-LGL)), treated with bendamustine. Partial (PR) and complete response (CR) rates were reached in nine (45 %) and two (10 %) patients, respectively, including three PR in T-NOS, one CR in AILT, three PR in T-PLL, two PR in MF/SS, and one CR and one PR in T-LGL lymphoma. The 6 months estimated progression free and overall survival was 44 and 67 %, respectively. Grade 3-4 neutropenia and thrombocytopenia were registered in 44 and 25 % of cases. Four patients developed major infectious complications. At a median follow-up of 6 months (range 1-18), 13 patients are alive and 7 patients died all because of lymphoma progression. Bendamustine deserves further investigation in patients with T cell neoplasms.
|
Authors | Francesco Zaja, Luca Baldini, Andrés J M Ferreri, Stefano Luminari, Alberto Grossi, Flavia Salvi, Renato Zambello, Maria Goldaniga, Stefano Volpetti, Renato Fanin |
Journal | Annals of hematology
(Ann Hematol)
Vol. 92
Issue 9
Pg. 1249-54
(Sep 2013)
ISSN: 1432-0584 [Electronic] Germany |
PMID | 23592272
(Publication Type: Journal Article, Multicenter Study)
|
Chemical References |
- Antineoplastic Agents, Alkylating
- Nitrogen Mustard Compounds
- Bendamustine Hydrochloride
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents, Alkylating
(therapeutic use)
- Bendamustine Hydrochloride
- Female
- Follow-Up Studies
- Humans
- Leukemia, Large Granular Lymphocytic
(diagnosis, drug therapy, epidemiology)
- Lymphoma, T-Cell
(diagnosis, drug therapy, epidemiology)
- Male
- Middle Aged
- Nitrogen Mustard Compounds
(therapeutic use)
- Retrospective Studies
- Salvage Therapy
(methods)
|